EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nanogel-mediated therapeutic delivery across blood-cerebrospinal fluid and blood-spinal cord barriers

Dharmeshkumar M. Modi, Akshat D. Modi

Brain Disorders · 2024-09 · 15 · 100151

DOI: 10.1016/j.dscb.2024.100151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Disorders, 2024-09. Verfasst von Dharmeshkumar M. Modi und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanogels are emerging as promising nanocarriers for delivering therapeutic agents to treat central nervous system (CNS) disorders. Traditional therapeutic approaches for CNS disorders are often hindered by the inability to cross the blood-cerebrospinal fluid barrier (BCSFB) and blood-spinal cord barrier (BSCB), necessitating high and frequent dosages that can lead to off-target effects. Nanogels, however, offer a unique solution by enabling targeted delivery across these barriers with minimal dosages and a controlled-release mechanism, marking a significant advancement in CNS treatment. This narrative review explores the current knowledge and recent advancements in the application of nanogels for CNS disorders. Specifically, it highlights how chitosan-based, polyethylene glycol-based, polypeptide-based, and dextran-based nanogels effectively cross the BCSFB, while macrophage membrane-encapsulated and polyethylene glycol-based nanogels traverse the BSCB. These nanogels are compatible with a range of therapeutic agents, including neural stem cells, metformin, methotrexate, rolipram, oncomodulin, and antagomir-21, targeting CNS disorders like spinal cord injury and intervertebral disc degeneration. Additionally, nanogels can be administered through various routes such as intravenous, intranasal, intrathecal, and intraganglionic methods. Despite these promising developments, further research is necessary to fully elucidate their mechanisms of action and optimize their therapeutic efficacy for clinical applications.

Zitieren

APA

Modi, D. M., & Modi, A. D. (2024). Nanogel-mediated therapeutic delivery across blood-cerebrospinal fluid and blood-spinal cord barriers. Brain Disorders, 15, 100151. https://doi.org/10.1016/j.dscb.2024.100151

Vancouver

Modi DM, Modi AD. Nanogel-mediated therapeutic delivery across blood-cerebrospinal fluid and blood-spinal cord barriers. Brain Disorders. 2024;15:100151. doi:10.1016/j.dscb.2024.100151

BibTeX
@article{Modi2024,
  author = {Modi, Dharmeshkumar M. and Modi, Akshat D.},
  title = {Nanogel-mediated therapeutic delivery across blood-cerebrospinal fluid and blood-spinal cord barriers},
  journal = {Brain Disorders},
  year = {2024},
  volume = {15},
  pages = {100151},
  doi = {10.1016/j.dscb.2024.100151}
}
Kostenlos starten →